chartexchange

Palisade Bio Reports Third Quarter 2026 Financial Results and Advances PALI-2108 Phase 2 Clinical Development Programs

GlobeNewswire Inc. | Nov 10, 2026 4:25 PM EST

First Patient Dosed in Global Phase 2b ASCENTRA-UC Trial; Topline Results Expected in Q4 2027

Read original article